Oral safety and efficacy of eucalypt sap resin in the management of recurrent vulvovaginal candidiasis
Pilot oral safety and efficacy of eucalypt sap resin for the management of recurrent vulvovaginal candidiasis (RVVC) and associated gastrointestinal symptoms: A comparative, 2-arm, double-blinded randomised study
Integria Healthcare (Australia) Pty Ltd.
24 participants
May 15, 2024
Interventional
Conditions
Summary
The purpose of this study is to assess safety of internal eucalypt sap resin consumption and also to explore if a low dose taken over a period of six months may be able to decrease vulvo-vaginal candidiasis episodes and concurrent gastrointestinal symptoms in women with recurrent vulvo-vaginal candidiasis (RVVC) and gastrointestinal symptoms of microbial imbalance. With the prevalence of RVVC and lack of safe long-term treatments for managing the symptoms of candida overgrowth (both gastrointestinal and vaginal), we are investigating this ingredient for potential in the management of RVVC alongside long-term safety.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be directed to take one capsule orally per day in the morning, with food for 24 weeks. Arm A capsules - contain 700 mg of powdered Eucalypt sap resin Compliance will be monitored by return capsule count A subset of women in each group (maximum n=12) will be offered vaginal microbiome testing. This is exploratory testing and will be offered at the researchers discretion.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12624000204549